The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.
Tentative FDA approval enables Lupin to prepare for commercial launch of generic enzalutamide once remaining exclusivity and patent constraints no longer block approval. Bioequivalence was established ...
CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1–6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without ...
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...
In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...
The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...
The SureForm 45 stapler is the first stapler cleared for single-port robotic surgery in the US, enhancing surgical control and efficiency. SmartFire technology in the stapler optimizes staple line ...
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
"The CF for 2025 is proposed to decrease to $32.36 from $33.29 in 2024. This is a decrease of 2.80%," write Jonathan Rubenstein, MD, and Mark Painter. On July 10, 2024, the Centers for Medicare & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results